Moxifloxacina Kabi (Moxifloxacin Hydrochloride)

• Moxifloxacin is a fluoroquinolone antibacterial that targets a broad spectrum of Gram‑negative and Gram‑positive bacteria.
• Community‑acquired bacterial pneumonia: achieves clinical cure and microbiological eradication in adult patients.
• Complicated intra‑abdominal infections: provides effective bacterial clearance after surgical source control.
• Skin and soft tissue infections: resolves infection signs and prevents progression.
• Acute bacterial sinusitis: reduces symptoms and eliminates causative pathogens.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to these enzymes, the drug prevents DNA synthesis and transcription, leading to bacterial cell death. This bactericidal action is effective against a wide range of aerobic Gram‑negative and Gram‑positive organisms, including atypical respiratory pathogens.

Moxifloxacina Kabi may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: loose stools, occasionally watery.
• Headache: transient cranial pain.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: can precipitate ventricular arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: severe diarrhea with pseudomembranous colitis.
• Hepatic failure: marked elevation of liver enzymes and jaundice.

Before initiating therapy, consider patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust dosing according to renal function and prescriber guidance.
• History of tendon disorders: avoid use or discontinue promptly if symptoms arise.
• QT prolongation risk: obtain baseline ECG and monitor cardiac rhythm during treatment.
• Concomitant antacids or multivitamins: separate administration by at least 2 hours to prevent reduced absorption.
• Pregnancy and lactation: prescribe only when benefits outweigh potential risks.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacina Kabi can interact with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Co‑administration with other fluoroquinolones: increased risk of cumulative toxicity.
• Concurrent use of QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk.
• Combination with NSAIDs: may amplify central nervous system stimulation and seizure risk.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce moxifloxacin absorption; separate dosing.
• Warfarin: potential enhancement of anticoagulant effect; monitor INR closely.
• Corticosteroids: increased likelihood of tendon rupture; observe for musculoskeletal symptoms.